Progyny, Inc. $PGNY Shares Bought by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp raised its holdings in Progyny, Inc. (NASDAQ:PGNY) by 53.5% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 95,305 shares of the company’s stock after acquiring an additional 33,200 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Progyny were worth $1,618,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Wellington Management Group LLP raised its holdings in Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after acquiring an additional 1,621,688 shares in the last quarter. Fort Washington Investment Advisors Inc. OH lifted its position in Progyny by 46.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after acquiring an additional 859,289 shares during the last quarter. Loomis Sayles & Co. L P acquired a new stake in shares of Progyny in the 4th quarter valued at about $19,917,000. Ameriprise Financial Inc. grew its position in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after acquiring an additional 545,431 shares during the last quarter. Finally, Norges Bank purchased a new position in Progyny during the 4th quarter worth $10,167,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Performance

PGNY opened at $31.37 on Thursday. The company has a market cap of $2.46 billion, a price-to-earnings ratio of 40.74, a PEG ratio of 2.44 and a beta of 1.01. Progyny, Inc. has a one year low of $16.10 and a one year high of $33.06. The business’s fifty day moving average is $28.29 and its two-hundred day moving average is $23.17.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.46 million. During the same quarter in the previous year, the business posted $0.17 earnings per share. The firm’s quarterly revenue was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, analysts predict that Progyny, Inc. will post 1.19 EPS for the current fiscal year.

Progyny declared that its board has authorized a stock buyback program on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other Progyny news, Director Kevin K. Gordon sold 5,500 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total transaction of $137,445.00. Following the transaction, the director owned 9,318 shares of the company’s stock, valued at $232,856.82. This represents a 37.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Mark S. Livingston sold 8,275 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $25.50, for a total value of $211,012.50. Following the sale, the chief financial officer owned 79,063 shares in the company, valued at $2,016,106.50. This trade represents a 9.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 36,916 shares of company stock worth $939,875 in the last 90 days. 9.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PGNY. Bank of America increased their target price on shares of Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Weiss Ratings upgraded Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, June 26th. Citigroup restated an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. BTIG Research increased their price target on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Finally, Leerink Partners set a $38.00 price objective on shares of Progyny in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.25.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.